The global digital polymerase chain reaction (dPCR) market is expected to grow at a CAGR of around 17.5% from 2020 to 2027 and expected to reach the market value of around US$ 780.5 Mn by 2027.
Because of its potential applications in cell biology, genetic engineering, and medical diagnostics, digital polymerase chain reaction (dPCR) technology has remained a "hot topic" over the last two decades. Several advanced techniques for sample dispersion, thermal cycling, and digital PCR output monitoring have been reported. Digital PCR (dPCR) is a technique for quantifying nucleic acids (DNA, RNA, cDNA). Digital polymerase chain reaction (dPCR) determines the number of DNA targets (copies) per reaction partition using appropriately validated assays and without the need for a standard curve. Reaction partitions can be fixed chambers in a micro fluidic device, known as chamber digital PCR (cdPCR), or aqueous-based droplets floating in oil, known as droplet digital PCR (ddPCR) (ddPCR).
COVID-19 impact on digital polymerase chain reaction (PCR) market
According to a report published by Medrxiv.org, ARS-CoV-2 nucleic acid detection by RT-PCR is one of the criteria approved by China FDA for COVID-19 diagnosis. However, both the Chinese and US CDCs reported inaccurate test results (for example, a high false negative rate and some false positive rate) when using the RT-PCR method. SARS-CoV-2 was detected using a digital PCR (dPCR) instrument DropX-2000 and assay kits in 108 clinical specimens from 36 patients, including pharyngeal swabs, stool, and blood from various days during hospitalization. The lower detection limit of the optimized dPCR is at least ten times lower than that of RT-PCR. The overall clinical detection accuracy of dPCR is 96.3%. When compared to RT-PCR, digital PCR has a lower limit of detection, sensitivity, and accuracy, allowing COVID-19 detection with fewer false negative and false positive results, particularly for tests with low viral load specimens. Furthermore, dPCR is effective at detecting both asymptomatic and suspected patients. By quantifying an internal reference gene from human RNA in the PCR reactions, digital PCR can rule out negative results caused by insufficient sample loading.
Digital Polymerase Chain Reaction (dPCR) market has 100% gains in virology applications
Virology currently has the most mature applications of dPCR for infectious disease diagnostics. dPCR has also found use in the rapidly growing field of gene therapy, allowing for the absolute quantification of viral gene vectors prior to administration as well as the measurement of vector copy numbers in target tissues. The superior precision provided by dPCR has also proven useful in emerging areas of virology, such as measuring cell-associated HIV DNA, HIV 2-LTR circles (a measure of failed HIV integration into the nucleus), cell-associated HIV RNA, and spliced HIV RNA, as well as estimating the size of the replication-competent HIV reservoir. Furthermore, the best application of dPCR in clinical testing is for the detection of inherited chromosomally integrated (ici) human herpes virus (HHV)-6. Furthermore, dPCR has been instrumental in identifying heterogeneity in WHO international standards for BK and JC viruses.
Technological advancements in dPCR to grow immensely in the coming years
Multiple dPCR assays have been described in medical practice for the detection of specific bacterial pathogens. For example, dPCR tests for Chlamydia trachomatis ocular infection and methicillin-resistant Staphylococcus aureus (MRSA) carriage have been expressly validated for clinical use. On the other hand, significant effort has been put into developing bacterial dPCR assays for food safety monitoring. When compared to standard practice methods, the use of dPCR in this context offers significant advantages in bypassing inhibitors that are inherent in many of the crude samples used as the substrate for testing, as well as greater simplicity and throughput in some cases. It should be noted that dPCR is still a developing technology, and the systems that are currently available are first- or, at best, second-generation platforms.
High cost of digital polymerase chain reaction (dPCR) impedes the growth of global market
Despite rising cases of infectious diseases such as cancer and genetic disorders, as well as the high prevalence of these conditions in developing countries, the use of dPCR in these areas is still relatively low. This is due to a lack of knowledge about dPCR and its advanced forms in developing countries. Furthermore, the high cost of these devices further limits market penetration.
The global digital polymerase chain reaction (dPCR) is segmented based on technology, product type, application, and end-user. By technology, the market is segmented as droplet digital PCR, chip based digital PCR, and Beaming digital PCR. Based on product type, the market is segregated as digital PCR systems, consumables & reagents, and software & services. By application, the market is segmented as research, clinical diagnostics, and forensic & others. Further, end-user is segmented as pharmaceuticals & biotechnology industries, clinical diagnostic laboratories, and universities & other organizations.
Based on technology, ddPCR has been a significant revenue contributor to the global digital polymerase chain reaction market in the past and is expected to maintain its dominance during the forecast period. This is because the ddPCR technique precisely measures the number of DNA molecules in each drop. Furthermore, massive sample partitioning is an important aspect of the droplet digital PCR technique, which raises the demand.
The software and services segment is expected to grow the fastest in the coming years. Because the software aids in the efficient management of digital PCR data it is one of the prominent factors that foster segmental growth. As a result, there is an increase in demand for these products, propelling market growth.
North America dominates; Asia Pacific records fastest growing CAGR for the digital polymerase chain reaction (dPCR) market
The market attractiveness index for digital PCRs is expected to rise in North America. The region is distinguished by technological advancements, increased R&D spending, and improved healthcare infrastructure.
Asia Pacific, on the other hand, is expected to have the fastest growing CAGR in the dPCR market in the coming years. Rising patient awareness will drive the Asia Pacific advanced digital polymerase chain reaction (dPCR) market in the coming years. This is one of the most important factors contributing to regional growth.
The leading players of the global digital polymerase chain reaction (dPCR) market comprise of Bio-Rad Laboratories, Inc., Fluidigm Corporation, JN Medsys, The Merck Group, QIAGEN, Stilla Technologies Inc., Sysmex Corporation, Combinati, Inc., Thermo Fisher Scientific, and among others
Market By Technology
Droplet Digital PCR
Chip Based Digital PCR
Beaming Digital PCR
Market By Product Type
Digital PCR Systems
Consumables & Reagents
Software & Services
Market By Application
Forensic & Others
Market By End User
Pharmaceuticals & Biotechnology Industries
Clinical Diagnostic Laboratories
Universities & Other Organizations
Digital polymerase chain reaction (dPCR) market is expected to reach a market value of around US$ 780.5 Mn by 2027.
The digital polymerase chain reaction (dPCR) market is expected to grow at a CAGR of around 17.5% from 2020 to 2027.
Based on product type, software & services segment is the leading segment in the overall market.
Technological advancement is one of the prominent factors that drive the demand for digital polymerase chain reaction (dPCR) market.
Bio-Rad Laboratories, Inc., Fluidigm Corporation, JN Medsys, The Merck Group, QIAGEN, Stilla Technologies Inc., Sysmex Corporation, Combinati, Inc., Thermo Fisher Scientific, and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years